NOVEMBER 03, 2022

Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19

Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure.
u00a0
  • A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population
  • A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population
  • The start of regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations in 2023
You are using a non-registered version of TNC FlipBook - PDF viewer for WordPress. Please register your copy of TNC FlipBook - PDF viewer for WordPress to receive updates & keep using without issues.Click Here to go to registration page.

Other Press Releases

Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half…

Read more

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong…

Read more

Biophytis to Participate in Four Key Events in Q4 2025 Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy: CF&B Midcap Events…

Read more

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial…

Read more

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial…

Read more

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Biophytis announces that the European Medicines Agency (EMA) has issued a favorable outcome on Part I of…

Read more